HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Nuclear Eg5 (kinesin spindle protein) expression predicts docetaxel response and prostate cancer aggressiveness.

Abstract
Novel biomarkers predicting prostate cancer (PCa) aggressiveness and docetaxel therapy response of PCa patients are needed. In this study the correlation between nuclear Eg5-expression, PCa docetaxel response and PCa aggressiveness was assessed. Immunohistochemical staining for nuclear Eg5 was performed on 117 archival specimens from 110 PCa patients treated with docetaxel between 2004 and 2012. Samples were histologically categorized as positive/negative. Median follow-up time from diagnosis was 11.6 years. Nuclear Eg5-expression was significantly related to docetaxel response (p=0.036) in tissues acquired within three years before docetaxel initiation. Nuclear Eg5-expression was not related to Gleason-score (p=0.994). Survival of patients after docetaxel initiation did not differ based on nuclear Eg5-expression (p=0.540). Analyzing samples taken before hormonal therapy, overall survival and time to docetaxel use were significantly decreased in patients with nuclear Eg5-expressing tumors (p<0.01). Eg5-positive nuclei were found more frequently in T4-staged tumors (p=0.04), Gleason 8-10 tumors (p=0.08), and in metastasized tumors (p<0.01). Multivariate analyses indicated that nuclear Eg5-expression may be an independent parameter for tumor aggressiveness. Limitations of a retrospective analysis apply. In conclusion, nuclear Eg5-expression may be a predictive biomarker for docetaxel response in metastatic castrate-resistant PCa patients and a prognostic biomarker for hormone-naive PCa patients. Prospective validation studies are needed.
AuthorsMichel D Wissing, Ellen S De Morrée, Vincent O Dezentjé, Jeroen T Buijs, Ronald R De Krijger, Vincent T H B M Smit, Wytske M Van Weerden, Hans Gelderblom, Gabri van der Pluijm
JournalOncotarget (Oncotarget) Vol. 5 Issue 17 Pg. 7357-67 (Sep 15 2014) ISSN: 1949-2553 [Electronic] United States
PMID25277178 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antineoplastic Agents
  • Biomarkers, Tumor
  • KIF11 protein, human
  • Taxoids
  • Docetaxel
  • Kinesins
Topics
  • Adenocarcinoma (drug therapy, pathology)
  • Aged
  • Antineoplastic Agents (therapeutic use)
  • Biomarkers, Tumor (analysis)
  • Cell Nucleus (metabolism)
  • Docetaxel
  • Drug Resistance, Neoplasm (physiology)
  • Humans
  • Immunohistochemistry
  • Kinesins (analysis, biosynthesis)
  • Male
  • Middle Aged
  • Prostatic Neoplasms (drug therapy, pathology)
  • Retrospective Studies
  • Taxoids (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: